The cooperation between Chinese and foreign pharmaceutical companies is becoming more and more frequent, and the cooperation methods are becoming more and more diversified

[Pharmaceutical Network Industry News] Affected by the changes in the pharmaceutical industry, strong alliances between pharmaceutical companies have become the norm in recent year.
It is understood that since the beginning of this year, a large number of domestic and foreign pharmaceutical companies have joined forces to achieve complementary advantages, further promoting R&D innovation and accelerating product commercializatio.
For example, on August 16, Qingdao Baheal Pharmaceutical C.
, Lt.
announced that it signed a renewal agreement with Takeda (China) Investment C.
, Lt.
in Qingdao, Chin.
Relying on Baheal Pharmaceutical's professional online and offline market commercialization capabilities, the two parties will continue to deepen the promotion of Takeda China's products including Dacoplon® (lansoprazole enteric-coated capsules), Pantoloc® (pantoprazole sodium) Enteric-coated tablets), Protoppin® (lansoprazole orally disintegrating tablets), including the commercialization of a variety of brand product.
It is understood that as early as 2017, Takeda China reached a retail channel commercialization cooperation with Baheal Pharmaceuticals for a number of its prescription drug brands in the digestive fiel.
Takeda China is the first multinational pharmaceutical company to sign a contract with Baheal Pharmaceuticals' health brand commercialization platfor.
During the cooperation period, with its professional brand commercialization capabilities, Baheal Pharma has successfully promoted the rapid release of value of Takeda series products in retail channels, and the sales performance has grown steadily, helping Chinese patients to benefit widel.
Regarding the cooperation again, Takeda China said that it highly recognizes Baheal Pharmaceutical's brand commercialization capabilities and has helped Takeda China's branded products to cover many patients in the past cooperatio.
This renewal hopes to use Baheal Pharmaceutical's professional third-party commercialization platform to continue to promote the deeper coverage of Takeda China's branded products and benefit more Chinese patients in a more efficient and convenient wa.
In the future, the two parties will fully integrate resources and explore ways of cooperation in more field.
Baheal Pharma also stated that it will continue to provide commercial escort services for Takeda series products by virtue of its professional capabilities in brand operation and digital marketing, help products to continuously release value, and work together to provide patients with disease treatment solution.
On August 5, Innovent Bio revealed that they will cooperate with Sanofi to accelerate the product development and market access of innovative oncology drugs, benefiting more Chinese patient.
Among them, the two parties will focus on accelerating the development and commercialization of two clinical-stage core potential first-in-Class tumor pipeline.
Specifically, these two products are SAR408701 (Tusamitamab Ravtansine; anti-CEACAM5 antibody-drug conjugate) and SAR444245 (non-alpha-biased IL-2.
For this cooperation, Innovent believes that it will bring long-term benefits and higher R&D capital benefits to the compan.
On July 25, Darui Biomedical Technology (Shanghai) C.
, Lt.
announced that it has obtained the global exclusive license for the chemical modification and delivery platform of Sanofi's small nucleic acid drug platform, as well as preclinical candidates for four undisclosed target.
dru.
It is understood that the technology platform provided by Sanofi is strategically helping Da Rui Bio to establish industry-leading advantages in oligonucleotide modification, delivery and nucleic acid biology in the rapidly growing fiel.
This will enable Darui Bio to significantly expand and accelerate the application of its small nucleic acid drug pipeline in hepatic and non-liver therapeutic area.
.
.
The industry predicts that, according to the current status of the industry, the cooperation between enterprises will become more frequent and the content of cooperation will be more abundant in the futur.
Under the multi-dimensional cooperation, it is expected that Chinese and foreign pharmaceutical companies will join hands in "going out" and "bringing in" to further accelerat.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyon.